Newer Systemic Antifungal Agents
- Helen W. BoucherAffiliated withDivision of Geographic Medicine and Infectious Diseases, Tufts-New England Medical Center
- , Andreas H. GrollAffiliated withImmunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute
- , Christine C. ChiouAffiliated withImmunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute
- , Thomas J. WalshAffiliated withImmunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The past few years have seen the advent of several new antifungal agents, including those of a new class and a new generation of an existing class. Caspofungin, the first available echinocandin, has greatly expanded the antifungal armamentarium by providing a cell wall-active agent with candidacidal activity as well as demonstrated clinical efficacy in the therapy of aspergillosis refractory to available therapy. In addition, in clinical trials, caspofungin had comparable efficacy to amphotericin B for candidaemia and invasive Candida infections. Caspofungin and two more recently introduced echinocandins, micafungin and anidulafungin, are available as intravenous formulations only and characterised by potent anti-candidal activity, as well as few adverse events and drug interactions.
Voriconazole, the first available second-generation triazole, available in both intravenous and oral formulations, has added a new and improved therapeutic option for primary therapy of invasive aspergillosis and salvage therapy for yeasts and other moulds. In a randomised trial, voriconazole demonstrated superior efficacy and a survival benefit compared with amphotericin B followed by other licensed antifungal therapy. This and data from a noncomparative study led to voriconazole becoming a new standard of therapy for invasive aspergillosis. Voriconazole has several important safety issues, including visual adverse events, hepatic enzyme elevation and skin reactions, as well as a number of drug interactions. Posaconazole, only available orally and requiring dose administration four times daily, shows encouraging efficacy in difficult to treat infections due to zygomycetes. Ravuconazole, available in both intravenous and oral formulations, has broad-spectrum in vitro potency and in vivo efficacy against a wide range of fungal pathogens. Clinical studies are underway.
Despite the advances offered with each of these drugs, the morbidity and mortality associated with invasive fungal infections remains unacceptable, especially for the most at-risk patients. For individuals with severe immunosuppression as a result of chemotherapy, graft-versus-host disease and its therapy, or transplantation, new drugs and strategies are greatly needed.
- Newer Systemic Antifungal Agents
Volume 64, Issue 18 , pp 1997-2020
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Division of Geographic Medicine and Infectious Diseases, Tufts-New England Medical Center, Boston, Massachusetts, USA
- 2. Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Building 10, Room 13N-240, Bethesda, Maryland, 20892, USA